TimeScale Financial’s TG Therapeutics TGTX Stock Holding History

TimeScale Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,087	Closed	-$16.3K	–	636
2023 Q1	$16.3K	Buy	+1,087	New	+$16.5K	﹤0.01%	301

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

TimeScale Financial's TGTX Position: Q2 2023 in Review

TimeScale Financial sold out of TG Therapeutics (TGTX) in Q2 2023, closing a stake of 1,087 shares — an estimated $16.3K sold.

TimeScale Financial first reported a position in TGTX in Q1 2023 and held it in 1 quarter. The position peaked at $16.3K in Q1 2023. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

TimeScale Financial reported no remaining TG Therapeutics position as of Q2 2023 after selling out during the quarter.
TimeScale Financial sold 1,087 TG Therapeutics shares in Q2 2023, an estimated $16.3K.
TimeScale Financial first reported a position in TG Therapeutics in Q1 2023 and held it in 1 quarter.
TimeScale Financial's TG Therapeutics position peaked at $16.3K in Q1 2023.
244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.